MA30090B1 - Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie - Google Patents
Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénieInfo
- Publication number
- MA30090B1 MA30090B1 MA31081A MA31081A MA30090B1 MA 30090 B1 MA30090 B1 MA 30090B1 MA 31081 A MA31081 A MA 31081A MA 31081 A MA31081 A MA 31081A MA 30090 B1 MA30090 B1 MA 30090B1
- Authority
- MA
- Morocco
- Prior art keywords
- schizophrenia
- treatment
- negative symptoms
- antagonist
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention divulgue et revendique une méthode de traitement de déficits cognitifs chez un patient atteint de la schizophrénie par l'administration audit patient d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur CB1 comme décrit dans la présente. Dans un autre aspect, cette invention divulgue et revendique également une combinaison d'un ou de plusieurs antagonistes du récepteur CB1 et d'un ou plusieurs agents antipsychotiques utiles dans le traitement de troubles psychiatriques. La combinaison de cette invention donne des résultats synergiques en ce que la combinaison améliore les symptômes positifs et négatifs de la schizophrénie, la prise de poids et la catalepsie.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74843405P | 2005-12-08 | 2005-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30090B1 true MA30090B1 (fr) | 2008-12-01 |
Family
ID=37964962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31081A MA30090B1 (fr) | 2005-12-08 | 2008-06-26 | Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie |
Country Status (23)
Country | Link |
---|---|
US (1) | US20080221078A1 (fr) |
EP (1) | EP1962834A2 (fr) |
JP (1) | JP2009518423A (fr) |
KR (1) | KR20080073737A (fr) |
CN (1) | CN101321523A (fr) |
AR (1) | AR056846A1 (fr) |
AU (1) | AU2006321907A1 (fr) |
BR (1) | BRPI0619541A2 (fr) |
CA (1) | CA2632673A1 (fr) |
CR (1) | CR9957A (fr) |
DO (1) | DOP2006000273A (fr) |
EC (1) | ECSP088505A (fr) |
IL (1) | IL191888A0 (fr) |
MA (1) | MA30090B1 (fr) |
NO (1) | NO20082923L (fr) |
PE (1) | PE20071092A1 (fr) |
RU (1) | RU2008127491A (fr) |
SV (1) | SV2008002929A (fr) |
TN (1) | TNSN08205A1 (fr) |
TW (1) | TW200803839A (fr) |
UY (1) | UY29995A1 (fr) |
WO (1) | WO2007067617A2 (fr) |
ZA (1) | ZA200803924B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
WO2007110449A1 (fr) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Composés de benzènesulfonamide et utilisation de ceux-ci |
US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US8937181B2 (en) | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
AU2008307572A1 (en) * | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | Substituted aryl sulfone derivatives as calcium channel blockers |
PT2234966E (pt) * | 2007-12-18 | 2013-12-19 | Sanofi Sa | Derivados de azetidinas, sua preparação e sua aplicação em terapia |
FR2925051B1 (fr) * | 2007-12-18 | 2010-05-21 | Sanofi Aventis | Derives d'azetidines,leur preparation et leur application en therapeutique |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
ES2886641T3 (es) | 2014-08-11 | 2021-12-20 | Angion Biomedica Corp | Inhibidores de citocromo P450 y sus usos |
CN107531631B (zh) | 2014-12-31 | 2021-09-03 | 安吉昂生物医药公司 | 用于治疗疾病的方法和药剂 |
MX2019002265A (es) | 2016-08-24 | 2019-10-30 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
US7485732B2 (en) * | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
EP1663215A1 (fr) * | 2003-09-02 | 2006-06-07 | Solvay Pharmaceuticals GmbH | Nouvelle utilisation medicale d'antagonistes selectifs du receptor cb1 |
WO2006017892A1 (fr) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Procedes d'amelioration du fonctionnement cognitif |
FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
-
2006
- 2006-12-06 PE PE2006001558A patent/PE20071092A1/es not_active Application Discontinuation
- 2006-12-06 DO DO2006000273A patent/DOP2006000273A/es unknown
- 2006-12-07 AU AU2006321907A patent/AU2006321907A1/en not_active Abandoned
- 2006-12-07 RU RU2008127491/15A patent/RU2008127491A/ru not_active Application Discontinuation
- 2006-12-07 EP EP06839095A patent/EP1962834A2/fr not_active Ceased
- 2006-12-07 BR BRPI0619541-5A patent/BRPI0619541A2/pt not_active IP Right Cessation
- 2006-12-07 CA CA002632673A patent/CA2632673A1/fr not_active Abandoned
- 2006-12-07 WO PCT/US2006/046547 patent/WO2007067617A2/fr active Application Filing
- 2006-12-07 AR ARP060105411A patent/AR056846A1/es not_active Application Discontinuation
- 2006-12-07 CN CNA2006800454370A patent/CN101321523A/zh active Pending
- 2006-12-07 KR KR1020087013697A patent/KR20080073737A/ko not_active Application Discontinuation
- 2006-12-07 JP JP2008544469A patent/JP2009518423A/ja not_active Abandoned
- 2006-12-08 TW TW095145876A patent/TW200803839A/zh unknown
- 2006-12-08 UY UY29995A patent/UY29995A1/es unknown
-
2008
- 2008-05-07 CR CR9957A patent/CR9957A/es not_active Application Discontinuation
- 2008-05-08 ZA ZA200803924A patent/ZA200803924B/xx unknown
- 2008-05-08 TN TNP2008000205A patent/TNSN08205A1/en unknown
- 2008-05-22 US US12/125,285 patent/US20080221078A1/en not_active Abandoned
- 2008-06-02 IL IL191888A patent/IL191888A0/en unknown
- 2008-06-06 SV SV2008002929A patent/SV2008002929A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008505A patent/ECSP088505A/es unknown
- 2008-06-25 NO NO20082923A patent/NO20082923L/no not_active Application Discontinuation
- 2008-06-26 MA MA31081A patent/MA30090B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20080221078A1 (en) | 2008-09-11 |
CR9957A (es) | 2008-09-22 |
UY29995A1 (es) | 2007-07-31 |
EP1962834A2 (fr) | 2008-09-03 |
WO2007067617A2 (fr) | 2007-06-14 |
SV2008002929A (es) | 2009-12-02 |
AR056846A1 (es) | 2007-10-24 |
PE20071092A1 (es) | 2007-12-10 |
ZA200803924B (en) | 2009-10-28 |
RU2008127491A (ru) | 2010-01-20 |
JP2009518423A (ja) | 2009-05-07 |
ECSP088505A (es) | 2008-08-29 |
CN101321523A (zh) | 2008-12-10 |
TW200803839A (en) | 2008-01-16 |
KR20080073737A (ko) | 2008-08-11 |
BRPI0619541A2 (pt) | 2011-10-04 |
TNSN08205A1 (en) | 2009-10-30 |
AU2006321907A1 (en) | 2007-06-14 |
CA2632673A1 (fr) | 2007-06-14 |
NO20082923L (no) | 2008-09-02 |
DOP2006000273A (es) | 2007-10-15 |
IL191888A0 (en) | 2009-08-03 |
WO2007067617A3 (fr) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30090B1 (fr) | Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie | |
MA31016B1 (fr) | Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine. | |
ATE477252T1 (de) | Substituierte diazepane als antagonisten an orexinrezeptoren | |
MA31451B1 (fr) | Antagonistes des recepteurs de l'orexine de pyridyl piperidine. | |
MA30900B1 (fr) | Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3 | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
UA100974C2 (ru) | Соединения замещенных диазепанов как антагонисты орексиновых рецепторов | |
MA35419B1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
WO2007126935A3 (fr) | Antagonistes des récepteurs de l'orexine sous forme de composés diazépane | |
MA34465B1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
FR2938437B1 (fr) | Utilisation cosmetique de microorganisme pour le traitement des peaux grasses | |
MA37525B1 (fr) | Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine | |
ATE503754T1 (de) | 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit | |
MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
EA200100936A1 (ru) | Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
NO20063856L (no) | Behandling av psykoser med quetiapin-antipsykotiske midler | |
MA34939B1 (fr) | Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation | |
FR2856596B1 (fr) | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. | |
MA32277B1 (fr) | Derives de 2-phenyl-4- cyclopropyl-pyrimidine | |
MA29339B1 (fr) | Derives du thiazole fondus ayant une affinite pour le recepteur de l'histamine h3 | |
EA201290764A1 (ru) | Способы и композиции для улучшения когнитивной функции | |
EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
MA33753B1 (fr) | Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci | |
TNSN07355A1 (fr) | Derives d'aryl-1,4-pyrazine substitues |